Eye on Washington

The American Academy of Pediatrics urges clinicians to offer confidential, adolescent-centered contraceptive care using evidence-based, equity-informed approaches.

Garadacimab-gxii is the only treatment to target factor Xlla for prophylactic use to prevent attacks of HAE in patients aged 12 years and older.

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.